Why Did Stan Druckenmiller Sell Broadcom Stock?
In Q3, legendary macro investor Stan Druckenmiller sold his entire…
Sell
24
RAFA Quote, Financials, Valuation and Earnings
Last price:
$0.0300
Seasonality move
:
-4.21%
Day range:
$0.0036 - $0.0386
52-week range:
$0.0036 - $0.1790
Dividend yield:
0%
P/E ratio:
14.12x
P/S ratio:
0.26x
P/B ratio:
0.22x
Volume:
97.8K
Avg. volume:
21.4K
1-year change:
-64.5%
Market cap:
$2.3M
Revenue:
$9.1M
EPS (TTM):
--
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target DownsideNo price target exists because of limited analyst coverage.
-
Price Target UpsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, Rafarma Pharmaceuticals, Inc. has -- downside to fair value with a price target of -- per share.
RAFA vs. S&P 500
-
Over the past 5 trading days, Rafarma Pharmaceuticals, Inc. has underperformed the S&P 500 by -20.68% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Rafarma Pharmaceuticals, Inc. does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Rafarma Pharmaceuticals, Inc. has grown year-over-year revenues for 2 quarters straight. In the most recent quarter Rafarma Pharmaceuticals, Inc. reported revenues of --.
Earnings Growth
-
Rafarma Pharmaceuticals, Inc. has grown year-over-year earnings for 2 quarters straight. In the most recent quarter Rafarma Pharmaceuticals, Inc. reported earnings per share of --.
Enterprise value:
2.2M
EV / Invested capital:
--
Price / LTM sales:
0.26x
EV / EBIT:
4.90x
EV / Revenue:
0.24x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-16.31x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
4.90x
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | $60M | $26.9M | $9.1M | $220K | $278K | |
| Gross Profit | $22.4M | $10.2M | $720K | $73K | $119K | |
| Operating Income | $6.5M | $1.9M | $456K | $31K | $82K | |
| EBITDA | $6.5M | $1.9M | $456K | $31K | $82K | |
| Diluted EPS | $0.06 | $0.01 | $0.00 | $0.00 | $0.00 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | -- | $46.8M | $46.2M | $2M | $1.8M | |
| Total Assets | -- | $81.6M | $87.3M | $12.2M | $12M | |
| Current Liabilities | -- | $15.7M | $13.8M | $1.7M | $1.6M | |
| Total Liabilities | -- | $17.7M | $16.2M | $1.7M | $1.6M | |
| Total Equity | -- | $63.9M | $71.1M | $10.5M | $10.4M | |
| Total Debt | -- | $449K | $459K | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $14.8M | -- | -$137K | $180K | -$1K | |
| Cash From Investing | -$7.7M | -- | $1K | $2K | $1K | |
| Cash From Financing | -$1.9M | -- | -$50K | -- | -- | |
| Free Cash Flow | $3.8M | -- | -$137K | $180K | -$1K | |
RAFA
Sector
Market Cap
$2.3M
--
Price % of 52-Week High
15.32%
--
Dividend Yield
0%
--
Shareholder Yield
--
--
1-Year Price Total Return
-64.5%
--
Beta (5-Year)
0.548
--
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$0.0351
200-day SMA
Sell
Level
$0.0722
Bollinger Bands (100)
Sell
Level
0.029 - 0.069
Chaikin Money Flow
Sell
Level
-62.1K
20-day SMA
Sell
Level
$0.0370
Relative Strength Index (RSI14)
Sell
Level
39.0880
ADX Line
Sell
Level
10.8673
Williams %R
Neutral
Level
-45.1037
50-day SMA
Sell
Level
$0.0368
MACD (12, 26)
Buy
Level
0.0097
25-day Aroon Oscillator
Sell
Level
-40
On Balance Volume
Sell
Level
-248.6K
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (3.2837)
Buy
CA Score
(Annual)
Level (1.6496)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (2)
Buy
Ohlson Score
Level (-0.1045)
Buy
Piotroski F Score
(Annual)
Level (7)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Rafarma Pharmaceuticals, Inc. engages in the manufacture and marketing of pharmaceutical goods. It produces all types of medical drugs in all delivery methods for various pharmacological groups. The company was founded in 1930 and is headquartered in Draper, UT.
Stock Forecast FAQ
In the current month, RAFA has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The RAFA average analyst price target in the past 3 months is --.
-
Where Will Rafarma Pharmaceuticals, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Rafarma Pharmaceuticals, Inc. share price will drop to -- per share over the next 12 months.
-
What Do Analysts Say About Rafarma Pharmaceuticals, Inc.?
Analysts are divided on their view about Rafarma Pharmaceuticals, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Rafarma Pharmaceuticals, Inc. is a Sell and believe this share price will rise from its current level to --.
-
What Is Rafarma Pharmaceuticals, Inc.'s Price Target?
The price target for Rafarma Pharmaceuticals, Inc. over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is RAFA A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Rafarma Pharmaceuticals, Inc. is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of RAFA?
You can purchase shares of Rafarma Pharmaceuticals, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Rafarma Pharmaceuticals, Inc. shares.
-
What Is The Rafarma Pharmaceuticals, Inc. Share Price Today?
Rafarma Pharmaceuticals, Inc. was last trading at $0.0300 per share. This represents the most recent stock quote for Rafarma Pharmaceuticals, Inc.. Yesterday, Rafarma Pharmaceuticals, Inc. closed at $0.0274 per share.
-
How To Buy Rafarma Pharmaceuticals, Inc. Stock Online?
In order to purchase Rafarma Pharmaceuticals, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get RAFA Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
RAFA
Sector
P/E ratio
14.12x
--
PEG ratio
--
--
P/B ratio
0.22x
--
Price / LTM sales
0.26x
--
Growth Metrics
RAFA
Sector
Revenue growth
--
--
Earnings growth
--
--
Revenue (5-year growth)
-4.52%
--
Earnings forecast
--
--
Profitability
RAFA
Sector
Profitability FY 2024
$674K
--
Return on invested capital
--
--
Return on assets
--
--
Return on equity
--
--
Earnings Date
Last Earnings Date
Jan
3
Next Earnings Date
Jan
3
Estimated Next Earnings Date
Apr
4
Balance Sheet
RAFA
Sector
Total cash
--
--
Short term investments
--
--
Total assets
$12M
--
Long term debt
--
--
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is CoreWeave Stock Down So Much?
AI cloud computing business CoreWeave (NASDAQ:CRWV) has been through a…
Why Did Stan Druckenmiller Buy MercadoLibre Stock?
In Q3, billionaire Stan Druckenmiller bought about 4,620 shares of…
Stock Ideas
Buy
55
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 36x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Sell
45
CTEV alert for Jan 2
Claritev Corp. [CTEV] is down 20.7% over the past day.
Sell
47
ASTS alert for Jan 2
AST Spacemobile, Inc. [ASTS] is up 14.94% over the past day.
Sell
45
BIDU alert for Jan 2
Baidu, Inc. [BIDU] is up 15.01% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
